[go: up one dir, main page]

PE20252310A1 - Anticuerpos anti-tgf-beta 1 latente y metodos de uso - Google Patents

Anticuerpos anti-tgf-beta 1 latente y metodos de uso

Info

Publication number
PE20252310A1
PE20252310A1 PE2025001626A PE2025001626A PE20252310A1 PE 20252310 A1 PE20252310 A1 PE 20252310A1 PE 2025001626 A PE2025001626 A PE 2025001626A PE 2025001626 A PE2025001626 A PE 2025001626A PE 20252310 A1 PE20252310 A1 PE 20252310A1
Authority
PE
Peru
Prior art keywords
beta
latent tgf
antibodies
antibody
tgf
Prior art date
Application number
PE2025001626A
Other languages
English (en)
Inventor
Masakazu Kanamori
Yuri Ikawa
Nasa Savory
Keita Mori
Kazuhide Shirai
Shuuki Takizawa
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of PE20252310A1 publication Critical patent/PE20252310A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invencion se refiere a unos anticuerpos anti-TGF-beta 1 latente; a un inmunoconjugado que comprende dicho anticuerpo junto con un agente citotoxico; a un acido nucleico aislado que codifica el anticuerpo; a un vector que contiene dicho acido nucleico; y a una celula huesped que lo alberga. Asimismo, la invencion se refiere a un metodo para producir el anticuerpo; asi como a una formulacion farmaceutica que comprende el anticuerpo anti-TGF-beta 1 latente o el inmunoconjugado, junto con un portador farmaceuticamente aceptable. Los anticuerpos anti-TGF-beta 1 latente inhiben la activacion mediada por peptidasa de TGF-beta 1 latente, sin afectar o afectando minimamente la activacion mediada por integrina de TGF-beta 1 latente. Ademas, estos anticuerpos presentan afinidad de union dependiente del pH hacia TGF-beta 1 latente.
PE2025001626A 2023-02-10 2024-02-09 Anticuerpos anti-tgf-beta 1 latente y metodos de uso PE20252310A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023019304 2023-02-10
PCT/JP2024/004456 WO2024166996A1 (en) 2023-02-10 2024-02-09 Anti-latent tgf-beta 1 antibodies and methods of use

Publications (1)

Publication Number Publication Date
PE20252310A1 true PE20252310A1 (es) 2025-09-22

Family

ID=92263024

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2025001626A PE20252310A1 (es) 2023-02-10 2024-02-09 Anticuerpos anti-tgf-beta 1 latente y metodos de uso

Country Status (14)

Country Link
US (1) US20240376190A1 (es)
EP (1) EP4662245A1 (es)
JP (1) JP2024119756A (es)
KR (1) KR20250148627A (es)
CN (1) CN120835902A (es)
AR (1) AR131841A1 (es)
AU (1) AU2024217529A1 (es)
CO (1) CO2025011604A2 (es)
CR (1) CR20250373A (es)
IL (1) IL322242A (es)
MX (1) MX2025009136A (es)
PE (1) PE20252310A1 (es)
TW (1) TW202448961A (es)
WO (1) WO2024166996A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120022360A (zh) 2019-08-28 2025-05-23 中外制药株式会社 跨物种抗潜伏TGF-β1抗体和使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011102483A1 (ja) 2010-02-19 2011-08-25 独立行政法人理化学研究所 ヒトTGF-βのLAPに結合する抗体
HK1245134A1 (zh) 2015-01-14 2018-08-24 The Brigham And Women's Hospital, Inc. 用抗lap单克隆抗体治疗癌症
BR112018068340A2 (pt) 2016-03-11 2019-01-15 Scholar Rock Inc imunoglobulinas de ligação ao tgfss1 e usos destas
WO2018043734A1 (en) 2016-09-05 2018-03-08 Chugai Seiyaku Kabushiki Kaisha Anti-tgf-beta 1 antibodies and methods of use
JP7315566B2 (ja) * 2018-02-23 2023-07-26 中外製薬株式会社 種交差性抗潜在型ＴＧＦ－β１抗体および使用方法
CN120022360A (zh) * 2019-08-28 2025-05-23 中外制药株式会社 跨物种抗潜伏TGF-β1抗体和使用方法

Also Published As

Publication number Publication date
AU2024217529A1 (en) 2025-08-07
EP4662245A1 (en) 2025-12-17
CN120835902A (zh) 2025-10-24
CO2025011604A2 (es) 2025-09-08
US20240376190A1 (en) 2024-11-14
TW202448961A (zh) 2024-12-16
JP2024119756A (ja) 2024-09-03
WO2024166996A1 (en) 2024-08-15
CR20250373A (es) 2025-10-03
MX2025009136A (es) 2025-09-02
KR20250148627A (ko) 2025-10-14
AR131841A1 (es) 2025-05-07
IL322242A (en) 2025-09-01

Similar Documents

Publication Publication Date Title
PE20252310A1 (es) Anticuerpos anti-tgf-beta 1 latente y metodos de uso
Nguyen et al. anti‐Markovnikov Hydroamination of Alkenes Catalyzed by a Two‐Component Organic Photoredox System: Direct Access to Phenethylamine Derivatives
PE20200839A1 (es) Anticuerpos anti-cd137
MX2019010282A (es) Formulacion de anticuerpos monoclonales.
EA201890796A1 (ru) Новое антитело к мезотелину и содержащая его композиция
MX2022015376A (es) Construcciones anti grupo de diferenciacion 93 (cd93) y usos de las mismas.
BR112023005674A2 (pt) Construtos anti-cd93 e usos dos mesmos
MX2022012541A (es) Inmunoconjugados.
ES8702941A1 (es) Un procedimiento para preparar un aducto de una resina efroxidica, un fenol polihidroxilado y un compuesto hidroxiaminico.
CO2019012108A2 (es) Nuevos ligadores peptídicos y conjugados de criptoficina, su preparación y su uso terapéutico
PE20241994A1 (es) Proteina mutante de interleucina-2 y fusion de la misma
MX2023001083A (es) Construcciones anti grupo de diferenciacion 93 (cd93) y usos de las mismas.
BR0210905A (pt) Anticorpos especìficos para cd44v6
Park et al. From noncovalent to covalent bonds: a paradigm shift in target protein identification
Lauwaet et al. Click chemistry-facilitated comprehensive identification of proteins adducted by antimicrobial 5-nitroimidazoles for discovery of alternative drug targets against giardiasis
BR112023008140A2 (pt) Composição para o condicionamento de materiais queratinosos
ES2194203T3 (es) Ligando del receptor tie-2 (ligando-4 de tie) y su uso.
Back et al. Multivalent interactions drive the Toxoplasma AC9: AC10: ERK7 complex to concentrate ERK7 in the apical cap
CO2025015280A2 (es) Anticuerpo o fragmento de unión a antígeno del mismo, conjugado de anticuerpo y fármaco y uso de los mismos
ZA202304872B (en) Anti-sclerostin constructs and uses thereof
Wilkes et al. Hydrocarbons and lipids: an introduction to structure, physicochemical properties, and natural occurrence
MX2023012707A (es) Anticuerpos de la proteina inmunorreceptora de celulas t con dominios ig e itim (anti-tigit) y metodos de uso de estos.
US9957294B2 (en) Compositions and methods for analyzing histidine phosphorylation
BR112022016491A2 (pt) Construto anti-cd137 e usos do mesmo
Boontheung et al. Negative ion electrospray mass spectra of caerulein peptides: an aid to structural determination